The United Kingdom and the United States have finalized a major trade agreement that will preserve zero tariffs on British drug shipments entering the US market.
Agreement Details of the Accord
As part of the deal, the UK has agreed to raise funding on medicines through the NHS. This move secures that duties on these key products will be held at zero for a timeframe of 36 months.
This development comes after earlier statements to hike tariffs on patented pharmaceutical products, with increases mentioned reaching 100%.
"This arrangement with the UK strengthens the global environment for new treatments and establishes long-overdue balance to transatlantic medicine commerce," a release said.
Commercial Significance
Medicines are one of the Britain's biggest goods shipped to the United States, which is by far the largest market for major companies like GSK and AstraZeneca.
Export figures indicate that in the one-year period leading up to September, the UK exported drugs totaling £11.1bn to the US. This value accounted for 17.4% of British export trade in that timeframe.
"This guarantee protects jobs, boosts investment and sets the stage for the UK to establish itself as a international leader for life sciences," the Business and Trade Secretary stated.
Detailed British Pledges
The pact includes several notable pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the cost ceiling at which it deems new treatments to be too expensive by 25%.
- Higher Drug Budget: There is a aim to raise overall NHS spending on treatments from 0.3% of Gross Domestic Product to 0.6% over the coming ten years.
- Rebate Cap: The amount manufacturers must refund to the NHS to prevent overspending will be limited at fifteen percent. Last year, refunds were more than 20%.
Broader Context
The deal takes place against a protracted tension between the pharmaceutical industry and the British authorities over drug pricing and NHS adoption.
This friction were heightened by arguments that US consumers were charged a premium for the equivalent treatments than consumers in the Britain and the EU.
In recent months, several large pharmaceutical investments in the UK have been paused or scrapped, while major funding commitments have been pledged toward US facilities.
The Science Minister publicly accepted that the NHS needed to invest a greater share on drugs, noting that its spending on drugs had shrunk as a share of its resources over the last ten years.
